Evaluation of Psilocybin (TRP-8802) in the Treatment of Binge Eating Disorder

PHASE2CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

March 16, 2022

Primary Completion Date

March 7, 2024

Study Completion Date

June 7, 2024

Conditions
Binge Eating Disorder
Interventions
DRUG

TRYP-0082

A single (1) 25 mg oral dose of TRP 8802 will be administered in a carefully monitored setting following 6 to 8 hours of preparatory psychotherapy. Subjects will be in the study for 12 weeks following the dose of TRP 8802 (until Week 14), approximately 5 months from initiation of screening through the last follow-up.

BEHAVIORAL

Psychotherapy

A single (1) 25 mg oral dose of TRP 8802 will be administered in a carefully monitored setting following 6 to 8 hours of preparatory psychotherapy. Subjects will be in the study for 12 weeks following the dose of TRP 8802 (until Week 14), approximately 5 months from initiation of screening through the last follow-up.

Trial Locations (1)

32608

University of Florida, Gainesville

Sponsors

Lead Sponsor

All Listed Sponsors
lead

TRYP Therapeutics

INDUSTRY

NCT05035927 - Evaluation of Psilocybin (TRP-8802) in the Treatment of Binge Eating Disorder | Biotech Hunter | Biotech Hunter